Inhibitory effect of commercial rhIGFBP-3 on human MCF-7 breast cancer cells and HT-29 colon cancer cells.

Abstract

<p>Different concentrations of commercial rhIGFBP-3 ranged from 9.375 ng/ml to 300 ng/ml were used to treat MCF-7 and HT-29 cells. Data are shown as means ± SD.</p